IN THE CLAIMS

Please amend the claims as follows.

1-22. Canceled.

~~23~~1. (currently amended) A method ~~for~~of activating a receptor, comprising bringing said receptor into contact with an amphiphilic drug-oligomer conjugate comprising a therapeutic compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled with ~~to~~ a hydrophilic moiety.

~~24~~2. (currently amended) The method of claim ~~18~~1, further characterized in that said conjugate exhibits activity ~~in~~ the without cleavage of the therapeutic compound from the oligomer.

~~25~~3. (currently amended) The method of claim ~~18~~1, wherein the receptor is a G-protein coupled receptor.

~~26~~4. (currently amended) The method of claim ~~18~~1, wherein the receptor is an ~~Opioid~~ opioid receptor.

~~27~~5. (currently amended) The method of claim ~~18~~1, wherein the receptor is ~~a Opioid~~ an opioid receptor~~;~~ selected from the group consisting of δ, μ, and κ.

~~28~~6. (currently amended) The method of claim ~~18~~1, wherein the hydrophilic moiety is selected from the group consisting of sugar and PEG_{1-7}.

~~29~~7. (currently amended) The method of claim ~~18~~1, wherein the hydrophilic moiety is

selected from the group consisting of fatty acid, alkyl 1-26, cholesterol and adamantane.

~~30~~8. (currently amended) The method of claim ~~1~~81, wherein the therapeutic compound is a peptide having an added N-terminal residue selected from the group consisting of proline~~,~~ and alanine.

~~31~~9. (currently amended) The method of claim ~~1~~81, wherein the therapeutic compound is a peptide or protein.

~~32~~10. (currently amended) The method of claim ~~1~~81, wherein the therapeutic compound is a peptide and the peptide is selected from the group consisting of: enkephalin, adrenocorticotropic hormone, adenosine deaminase, ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminease, asparaginase, caerulein, calcitonin, chemotrypsin, cholecystokinin, clotting factors, dynorphins, ~~endorphins,~~ endorphins, enkephalins, ~~enkephalins,~~ erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalmic releasing factors, interferon, katacalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, ~~oxytosin~~oxytocin, papain, parathyroid hormone, ~~peptides~~ prolactin, soluble CD-4, somatomedin, somatostatin, ~~somatostatin,~~ somatotropin. superoxide dismutase, thyroid stimulating hormone, tissue plasminogen activator, trypsin, vasopressin, and analogues and active fragments of such peptides.

~~33~~11. (currently amended) The method of claim ~~1~~81, wherein the amphiphilic oligomer is selected from the group consisting of:

$CH_3(CH_2)_n(OC_2H_4)_mOH$ (Formula 1);

wherein n=3 to 25 and m=1 to 6;

$CH_3(CH_2)_n(OC_2H_4)_mOCH_2CO_2H$ (Formula 2);

wherein n=3 to 25 and m=1 to 7;

$CH_3(CH_2)_nCX(OC_2H_4)_mOH$ (Formula 3);

wherein n=3 to 25, m=1 to 7 and X=O or N;

$R\text{-}(OC_2H_4)_mCH_2CO_2H$ (Formula 4);

wherein m=0 to 5 and R=cholesterol or adamantane; ~~or~~

$R\text{-}OCO(C_2H_4O)_mCH_2CO_2H$ (Formula 5);

wherein m=0 to 5;

$CH_3(CH_2—CH=CH)_6(CH_2)_2CH_2(OC_2H_4)_mOH$ (Formula 6);

wherein m=0 to 7; and

$CH_3(CH_2—CH=CH)_6(CH_2)_2C_x(OC_2H_4)_mOH$ (Formula 7);

wherein m=1 to 7 and X=N or O.

~~34~~12. (currently amended) The method of claim ~~1~~81, wherein the hydrophilic moiety is coupled to the hydrophobic moiety by a hydrolyzable bond.

~~35~~13. (currently amended) The method of claim ~~1~~81, wherein the hydrophilic moiety is

coupled to the hydrophobic moiety by a non-hydrolyzable bond.

36-63. Canceled.

~~64~~14. (new and currently amended) The method of claim 1, wherein the therapeutic compound is an opioid receptor agonist, antagonist or partial agonist/partial antagonist.

~~65~~15. (new and currently amended) The method of claim 1, wherein the therapeutic compound is an enkephalin.